Christopher Church, MD
Otolaryngology · Loma Linda, CANPI 1932137171
Payments from drug & device makers
Across 28 payments — averaging $235.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Osteogenics Biomedical Inc.$5K
- Stryker$878
- Sanofi$187
- Amgen$125
- AstraZeneca$98
- Travere Therapeutics, Inc.$52
- plus $122 from 4 others
What the payments were for
- Speaking & faculty fees$5,00076%
- Travel & lodging$1382%
- Food & beverage$1,40821%
- Education$521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Osteogenics Biomedical Inc. | 2 | $5,138 |
| Stryker | 10 | $878 |
| Sanofi | 2 | $187 |
| Amgen | 1 | $125 |
| AstraZeneca | 1 | $98 |
| Travere Therapeutics, Inc. | 8 | $52 |
| Medtronic | 1 | $40 |
| Kls-martin L.p. | 1 | $40 |
| Intersect ENT, Inc. | 1 | $27 |
| Conmed Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPRESS ENT DILATION SYSTEM$519
- DUPIXENT$244
- Tavneos$125
- SCOPIS ENT$105
- N/A$105
How this compares
$6,598 in reported general payments places this provider in the 85th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 74 | $289,522 |
| Dupixent SyringeDupilumab | 36 | $139,290 |
| XhanceFluticasone Propionate | 13 | $8,362 |
| Fluticasone Propionate | 272 | $6,133 |
| Ipratropium Bromide | 82 | $3,847 |
| Azelastine Hcl | 40 | $1,676 |
| Montelukast Sodium | 27 | $360 |
| Ibuprofen | 13 | $277 |
| Famotidine | 28 | $265 |
| Levocetirizine Dihydrochloride | 12 | $218 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $168 |
| Prednisone | 70 | $159 |
| Omeprazole | 13 | $131 |
| Azithromycin | 39 | $130 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $78 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Loma Linda
- Randall OwRoseville$4.3M
- Amir MoradiVista$2.6M
- Brian WeeksSan Diego$1.6M
- Charles LimbSan Francisco$1.5M
- Andrew BerosSan Diego$688K
- Paul SchalchChula Vista$573K
- Steven DavisTorrance$544K
- Arnaud BewleySacramento$541K
- Keith BlackwellLos Angeles$349K
- Kalpna DurairajSun Valley$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.